Bayesian Modeling Assessing the Effectiveness of a Vaccination Strategy to Prevent HPV-related Diseases: the BEST Study

Giampiero Favato, Gianluca Baio, Alessandro Capone, Andrea Marcellusi, Silvano Costa, Giorgia Garganese, Mauro Picardo, Mike Drummond, Bengt Jönsson, Giovanni Scambia, Peter Zweifel, Francesco Saverio Mannini

gianluca@stats.ucl.ac.uk

8th World Congress in Health Economics
Sheraton Centre Toronto Hotel

iHEA, 11 July 2011
Outline of presentation

1. Health economic evaluations
2. Markov models
3. HPV and its clinical management
4. Statistical modelling
   - Distributional assumptions
5. Cost-effectiveness analysis
6. Conclusions
Outline of presentation

1. Health economic evaluations
2. Markov models
3. HPV and its clinical management
4. Statistical modelling
   - Distributional assumptions
5. Cost-effectiveness analysis
6. Conclusions
Outline of presentation

1. Health economic evaluations
2. Markov models
3. **HPV and its clinical management**
4. Statistical modelling
   - Distributional assumptions
5. Cost-effectiveness analysis
6. Conclusions
Outline of presentation

1. Health economic evaluations
2. Markov models
3. HPV and its clinical management
4. **Statistical modelling**
   - Distributional assumptions
5. Cost-effectiveness analysis
6. Conclusions
Outline of presentation

1. Health economic evaluations
2. Markov models
3. HPV and its clinical management
4. Statistical modelling
   - Distributional assumptions
5. **Cost-effectiveness analysis**
6. Conclusions
Outline of presentation

1. Health economic evaluations
2. Markov models
3. HPV and its clinical management
4. Statistical modelling
   - Distributional assumptions
5. Cost-effectiveness analysis
6. Conclusions
**Objective:** Combine costs & benefits of a given intervention into a rational scheme for allocating resources

- Recently, models have been built upon more advanced statistical foundations
- This problem can be formalised within a statistical decision-theoretic approach. Rational decision-making is effected through the comparison of expected utilities
**Objective:** Combine costs & benefits of a given intervention into a rational scheme for allocating resources

- Recently, models have been built upon more advanced statistical foundations
- This problem can be formalised within a statistical decision-theoretic approach. Rational decision-making is effected through the comparison of expected utilities

**Increasingly under a Bayesian framework**

  - Specific focus on Bayesian decision-theoretic development of cost-effectiveness analysis
- Contributions by several scholars and research groups
  - Tony O’Hagan (University of Sheffield — Centre for Bayesian Statistics in Health Economics)
  - Karl Claxton, Mike Sculpher (University of York)
Markov models

- Assume a set of “clinically relevant” states
  - Exhaustive and mutually exclusive
- The structure (links among nodes) describes the dynamics of disease history
  - Arrows connecting two states encode the assumption that a transition from
    the one where the arrow originates to the one reached by it is possible
  - Absence of an arrow between two states implies that the transition from one
to the other is not allowed by our model
Markov models

- Assume a set of “clinically relevant” states
  - Exhaustive and mutually exclusive
- The structure (links among nodes) describes the dynamics of disease history
  - Arrows connecting two states encode the assumption that a transition from the one where the arrow originates to the one reached by it is possible
  - Absence of an arrow between two states implies that the transition from one to the other is not allowed by our model
- From one period to the next, subjects can move among the states according to the rules specified by the arrows
- Movements occur according to suitable transition probabilities

\[ p_t = p_{t-1} \Lambda_t \]

where
- \( p_t \) is the vector of probabilities for each state at time \( t \)
- \( \Lambda_t = [\Lambda_t; j, h] \) is a transition matrix describing the probability of moving from state \( j \) to state \( h \) at time \( t \)
Markov models

1. Define a structure

- Disease
- In health
- Recovery
- Death

Transition probabilities:
- \( \lambda_{11} \)
- \( \lambda_{12} \)
- \( \lambda_{22} \)
- \( \lambda_{24} \)
- \( \lambda_{14} \)
- \( \lambda_{31} \)
- \( \lambda_{34} \)
- \( \lambda_{23} \)
2. Estimate the transition probabilities
3. Run the simulation: $t = 0$
3. Run the simulation: $t = 1$
3. Run the simulation: $t = 2$
3. Run the simulation: $t = 3$
3. Run the simulation: $t = T$
HPV and its management

- Human Papillomavirus (HPV) is the *primum movens* both in the etiopathogenesis of invasive cervical cancer and in other malignant and benign neoplastic lesions
- In most western countries, screening programmes have been established to detect and treat early instances of infection-related diseases
- Vaccination programmes have been suggested as an effective alternative, but the disease process is complicated so there is uncertainty over the cost-effectiveness
• Human Papillomavirus (HPV) is the *primum movens* both in the etiopathogenesis of invasive cervical cancer and in other malignant and benign neoplastic lesions

• In most western countries, screening programmes have been established to detect and treat early instances of infection-related diseases

• Vaccination programmes have been suggested as an effective alternative, but the disease process is complicated so there is uncertainty over the cost-effectiveness

• Our objective is compare the two interventions
  - $i = 0$: screening only (current standard)
  - $i = 1$: screening + multi-cohort quadrivalent vaccination
What’s the story?

Genital warts → Clearance → Reinfection

Healthy → Exposure → Infection

CIN1 → Reinfection

CIN2 → Reinfection

CIN3 → Death

Cervical cancer → Year 1 → Year 2 → Year 3

Gianluca Baio et al (The BEST Study)
Model parameters

- The set of transition probabilities is modelled according to some probabilistic relationships that we define with suitable parameters.
- We modelled the parameters assuming prior local independence.
• The set of transition probabilities is modelled according to some probabilistic relationships that we define with suitable parameters
• We modelled the parameters assuming prior local independence
• When data were directly available, we imposed minimally informative (flat) prior distributions and used the data to inform the ensuing posteriors
• In case hard data were not directly available, we encoded the information provided by literature review or expert opinion elicitation in suitable informative prior distributions
Model parameters

- The set of transition probabilities is modelled according to some probabilistic relationships that we define with suitable parameters.
- We modelled the parameters assuming prior local independence.
- When data were directly available, we imposed minimally informative (flat) prior distributions and used the data to inform the ensuing posteriors.
- In case hard data were not directly available, we encoded the information provided by literature review or expert opinion elicitation in suitable informative prior distributions.
- Moreover, we used official data from registry or population databases to get information on the age-specific mortality rates, incidence of genital warts and probability of sexual activity.
## Vaccine-related parameters

<table>
<thead>
<tr>
<th>Variable</th>
<th>Description</th>
<th>Distributional assumption</th>
<th>Mean</th>
<th>95% Cred Int</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\gamma$</td>
<td>Vaccine effectiveness</td>
<td>Informative LogNorm</td>
<td>0.7830</td>
<td>0.6830 0.8960</td>
</tr>
<tr>
<td>$\mu$</td>
<td>Vaccine compliance</td>
<td>Flat Beta</td>
<td>1.0000</td>
<td>0.9990 1.0000</td>
</tr>
<tr>
<td>$\alpha$</td>
<td>Vaccine coverage rate</td>
<td>Flat Beta</td>
<td>0.8470</td>
<td>0.8340 0.8600</td>
</tr>
<tr>
<td>$\omega_1$</td>
<td>Probability 1 shot</td>
<td>Flat Dirichlet</td>
<td>0.0000</td>
<td>0.0000 0.0010</td>
</tr>
<tr>
<td>$\omega_2$</td>
<td>Probability 2 shots</td>
<td>Flat Dirichlet</td>
<td>0.0000</td>
<td>0.0000 0.0010</td>
</tr>
<tr>
<td>$\omega_3$</td>
<td>Probability 3 shots</td>
<td>Flat Dirichlet</td>
<td>1.0000</td>
<td>0.9999 1.0000</td>
</tr>
<tr>
<td>$\xi$</td>
<td>Reduction in risk due to cross protection</td>
<td>Informative LogNorm</td>
<td>0.0740</td>
<td>0.0410 0.1290</td>
</tr>
<tr>
<td>$\chi$</td>
<td>Decrease in effectiveness due to non compliance</td>
<td>Informative Beta</td>
<td>0.5040</td>
<td>0.3110 0.7020</td>
</tr>
</tbody>
</table>

## Screening-related parameters

<table>
<thead>
<tr>
<th>Variable</th>
<th>Description</th>
<th>Distributional assumption</th>
<th>Mean</th>
<th>95% Cred Int</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\sigma_a$</td>
<td>Screening rate</td>
<td>Informative Beta</td>
<td>0.0500</td>
<td>0.0500 0.0500</td>
</tr>
<tr>
<td>$\sigma_a$</td>
<td>12-24 yo</td>
<td>Informative Beta</td>
<td>0.1530</td>
<td>0.1480 0.1590</td>
</tr>
<tr>
<td>$\sigma_a$</td>
<td>25-29 yo</td>
<td>Informative Beta</td>
<td>0.2150</td>
<td>0.2100 0.2190</td>
</tr>
<tr>
<td>$\sigma_a$</td>
<td>30-34 yo</td>
<td>Informative Beta</td>
<td>0.2460</td>
<td>0.2440 0.2470</td>
</tr>
<tr>
<td>$\sigma_a$</td>
<td>35-44 yo</td>
<td>Informative Beta</td>
<td>0.2600</td>
<td>0.2540 0.2660</td>
</tr>
<tr>
<td>$\sigma_a$</td>
<td>45-54 yo</td>
<td>Informative Beta</td>
<td>0.2420</td>
<td>0.2320 0.2520</td>
</tr>
<tr>
<td>$\sigma_a$</td>
<td>55-64 yo</td>
<td>Informative Beta</td>
<td>0.1840</td>
<td>0.1640 0.2020</td>
</tr>
<tr>
<td>$\sigma_a$</td>
<td>65-74 yo</td>
<td>Informative Beta</td>
<td>0.1080</td>
<td>0.0920 0.1250</td>
</tr>
</tbody>
</table>
Economic measures

Costs

- For each relevant state in the model, costs are defined as the product between the unit cost (specified as parameters) and the total number of subjects who are in that state at any given time.
- For example, for each intervention and time of the simulation, the cost associated with cervical cancer is

\[ C_{i,t}^{\text{can}} = \sum_{r=1}^{4} \beta_r C_{a_{i,t}} \left( c_{r}^{\text{can}} + 2c_{pap} + 2c_{col} + c_{dna} \right) \]

where \( C_{a_{i,t}} \) is the number of people who are in the state “cancer” at time \( t \) under strategy \( i \).
Economic measures

Costs

- For each relevant state in the model, costs are defined as the product between the unit cost (specified as parameters) and the total number of subjects who are in that state at any given time.
- For example, for each intervention and time of the simulation, the cost associated with cervical cancer is

\[ C_{i,t}^{\text{can}} = \sum_{r=1}^{4} \beta_r C_{a,i,t} (c_{r}^{\text{can}} + 2c_{\text{pap}} + 2c_{\text{col}} + c_{\text{dna}}) \]

where \( C_{a,i,t} \) is the number of people who are in the state “cancer” at time \( t \) under strategy \( i \).
- The present value of cost is then

\[ PVC_i = \sum_{t=1}^{T} \frac{C_{i,t}}{(1 + v_c)(t-1)} \]

where \( v_c \) is the costs discount rate and \( C_{i,t} \) is the sum of all costs.
Utilities

- Similarly, we can estimate the overall utility for each relevant state in the model as the product between the unit utilities (specified as parameters) and the total number of subjects who are in that state at any given time.

- The present value of utility is then

\[
PVU_i = \sum_{t=1}^{T} \frac{U_{i,t}}{(1 + v_u)^{(t-1)}}
\]

where \(v_u\) is the benefit discount rate and \(U_{i,t}\) is the sum of all utilities.
Economic analysis

Assume that all the parameters are included in a vector \( \theta = (\theta^1, \theta^0) \). Then the relevant quantities for the economic analysis are

- **The increment in the average clinical benefits:**
  \[
  \Delta_e = E[PVU \mid \theta^1] - E[PVU \mid \theta^0]
  \]

- **The increment in the average costs:**
  \[
  \Delta_c = E[PVC \mid \theta^1] - E[PVC \mid \theta^0]
  \]

- **The expected incremental benefit:**
  \[
  EIB = kE[\Delta_e] - E[\Delta_c] = U^1 - U^0
  \]

The distributions of these quantities can be estimated using the simulated values for the parameters in \( \theta \)
Cost-effectiveness plane

Vaccination + Screening vs Status quo

ICER = $120.12$

$k = 25000$
Cost-effectiveness plane contour plot
Vaccination + Screening vs Status quo

\[ \Pr(\Delta_e \leq 0, \Delta_c > 0) = 0 \]

\[ \Pr(\Delta_e > 0, \Delta_c > 0) = 0.991 \]

\[ \Pr(\Delta_e \leq 0, \Delta_c \leq 0) = 0 \]

\[ \Pr(\Delta_e > 0, \Delta_c \leq 0) = 0.009 \]
Cost Effectiveness Acceptability Curve

Probability of cost effectiveness vs. Willingness to pay

---

Gianluca Baio et al ( )
The BEST Study
8th World iHEA, Toronto, 11/07/2011
Use net benefit utility
\[ u(e, c, i) = k e_i - c_i \]
but consider varying \( k \).

CEAC represents
\[ \Pr(k \Delta e - \Delta c > 0 \mid \text{Data}) \]
as a function of \( k \).

Suggested as the standard tool for PSA by NICE.
- Use net benefit utility
  \[ u(e, c, i) = ke_i - c_i, \]
  but consider varying \( k \)

- CEAC represents
  \[ \Pr(k\Delta_e - \Delta_c > 0 \mid \text{Data}) \]
  as a function of \( k \)

- Suggested as the standard tool for PSA by NICE

- Summarises the probability of cost effectiveness, as it depends on the willingness to pay parameter \( k \)

- Meaningful only if the parameters are considered random, i.e. within the Bayesian framework
Expected value of information

(EVPI per patient: € 12.8)
Expected value of information

- Defined as
  \[ E[\max_i u(e, c, i) | \theta] - U^* \]
- Describes the average opportunity loss
- Equivalently, it is the maximum amount the decision maker should be willing to pay to resolve the uncertainty in the parameters

(EVPI per patient: € 12.8)
Expected value of information

- Defined as
  \[ E \left[ \max_i u(e, c, i) \mid \theta \right] - U^* \]

- Describes the **average opportunity loss**

- Equivalently, it is the maximum amount the decision maker should be willing to pay to *resolve the uncertainty* in the parameters

- By construction, combines
  1. *how much* we are likely to lose if we take the “wrong” decision
  2. *how likely* it is that we take it

- Drives the process of gathering additional evidence

(EVPI per patient: € 12.8)
Multicohort analysis: 12-15-18-25 yo

Cost Effectiveness Acceptability Curve

- Willingness to pay
- Probability of cost effectiveness

Gianluca Baio et al (The BEST Study)
8th World iHEA, Toronto, 11/07/2011
Conclusions

- The strategy that combines a multi-cohort quadrivalent-based vaccination and screening seems to be cost-effective as compared to screening only.
- Uncertainty in the model parameter is first integrated out (i.e. computing the expected utilities) and then accounted for separately (PSA).
- The optimal decision does not seem to be affected by this uncertainty.
Conclusions

- The strategy that combines a multi-cohort quadrivalent-based vaccination and screening seems to be cost-effective as compared to screening only.
- Uncertainty in the model parameter is first integrated out (i.e. computing the expected utilities) and then accounted for separately (PSA).
- The optimal decision does not seem to be affected by this uncertainty.
- The model can be modified to include more complex situations:
  - “Herd” immunity: vaccinating girls will protect boys, which in turn will protect more girls.
  - Different scenarios in terms of provision of health care: limited vaccine effectiveness (booster), specific economic conditions (partial vs complete reimbursement).
  - Vaccination of males.
Thank you!